Background: The approval of an increasing number of disease modifying drugs for the treatment of Multiple Sclerosis (MS) creates new challenges for patients and clinicians on the first treatment choice. The main aim of this study was to assess factors impacting first therapy choice in a large Italian MS cohort. Methods: Newly diagnosed relapsing -remitting (RR) MS patients (2010-2018) followed in 24 Italian MS centres were included in the study. We evaluated the association of baseline demographics, clinical and MRI char- acteristics to the first treatment choice by logistic regression models applied to pre -de fined binary alternatives:
Maniscalco, G.t., Saccà, F., Lanzillo, R., Annovazzi, P., Baroncini, D., Binello, E., et al. (2020). First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 42, 102059 [10.1016/j.msard.2020.102059].
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study
Mataluni, Giorgia;Landi, Doriana;
2020-07-01
Abstract
Background: The approval of an increasing number of disease modifying drugs for the treatment of Multiple Sclerosis (MS) creates new challenges for patients and clinicians on the first treatment choice. The main aim of this study was to assess factors impacting first therapy choice in a large Italian MS cohort. Methods: Newly diagnosed relapsing -remitting (RR) MS patients (2010-2018) followed in 24 Italian MS centres were included in the study. We evaluated the association of baseline demographics, clinical and MRI char- acteristics to the first treatment choice by logistic regression models applied to pre -de fined binary alternatives:File | Dimensione | Formato | |
---|---|---|---|
Maniscalco2020.pdf
solo utenti autorizzati
Licenza:
Non specificato
Dimensione
516.82 kB
Formato
Adobe PDF
|
516.82 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.